Systemic benefits of cyclic ovarian function

被引:5
|
作者
Berga, SL [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA
[3] Magee Womens Hosp, Magee Womens Res Inst, Pittsburgh, PA 15213 USA
关键词
ovulatory function; estradiol; brain;
D O I
10.1016/S1071-5576(00)00095-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To consider the systemic benefits of cyclic ovarian function. METHODS: Review and interpretation of extant data and concepts, with a focus on the physiologic impact of gonadal steroid exposures upon key nonreproductive target tissues in women. RESULTS: The role of cyclic ovarian function in reproductive processes such as menstruation, folliculogenesis, and conception is well understood. Less is known about the impact of the characteristic sex steroid fluctuations associated with ovulatory menstrual cycles upon what are typically viewed as a nonreproductive tissues, such as the limbic lobe and cerebral cortex. The explosion in knowledge regarding the molecular mechanisms of steroid action has expanded our appreciation of the complex and often subtle nature of this impact. CONCLUSIONS: A clear understanding of the systemic benefits of cyclic ovarian function is required to advise patients adequately about the risks and benefits of exogenous hormone use for the remediation or induction of anovulatory states. The inherent complexity of steroid hormone action coupled with the recognition that there is a long list of reproductive and nonreproductive target tissues obviates simple statements about the risks and benefits of hormonal manipulation and anovulatory states. (J Soc Gynecol Investig 2001;8:S3-S6) Copyright (C) 2001 by the Society for Gynecologic Investigation.
引用
收藏
页码:S3 / S6
页数:4
相关论文
共 50 条
  • [41] Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy
    Blumenfeld, Z
    Shapiro, D
    Shteinberg, M
    Avivi, I
    Nahir, M
    LUPUS, 2000, 9 (06) : 401 - 405
  • [42] Risks and Benefits of Taxanes in Breast and Ovarian Cancer
    Laura Boehnke Michaud
    Vicente Valero
    Gabriel Hortobagyi
    Drug Safety, 2000, 23 : 401 - 428
  • [43] Risks and benefits of taxanes in breast and ovarian cancer
    Michaud, LB
    Valero, V
    Hortobagyi, G
    DRUG SAFETY, 2000, 23 (05) : 401 - 428
  • [44] Pulmonary and ovarian manifestations of systemic mastocytosis
    Avila, NA
    Worobec, AS
    Ling, A
    Hijazi, Y
    Metcalfe, DD
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 166 (04) : 969 - 970
  • [45] SYSTEMIC AMYLOIDOSIS AND OVARIAN-CARCINOMA
    FERNANDEZMIRANDA, C
    MATEO, S
    GONZALEZGOMEZ, C
    BALLESTIN, C
    POSTGRADUATE MEDICAL JOURNAL, 1994, 70 (825) : 505 - 506
  • [46] Ovarian histoplasmosis in systemic lupus erythematosus
    Isotalo, PA
    McCarthy, AE
    Eidus, L
    PATHOLOGY, 2000, 32 (02) : 139 - 141
  • [47] OVARIAN TUMORS HISTOGENESIS AND SYSTEMIC EFFECTS
    FOX, H
    CALIFORNIA MEDICINE, 1968, 109 (04): : 295 - +
  • [48] Primary systemic therapy of ovarian cancer
    Pfisterer, J.
    Hilpert, F.
    Mahner, S.
    Harter, P.
    du Bois, A.
    GYNAKOLOGE, 2013, 46 (08): : 541 - 546
  • [49] Biomarkers for Systemic Therapy in Ovarian Cancer
    Penzvalto, Zsofia
    Surowiak, Pawel
    Gyorffy, Balazs
    CURRENT CANCER DRUG TARGETS, 2014, 14 (03) : 259 - 273
  • [50] Systemic treatment of primary ovarian cancer
    Selcuk, Ilker
    Yaznil, Muhammad Rizki
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : 5 - 6